Biotia

Taking the guesswork out of infectious diseases

We are advancing infectious disease diagnostics for patients managing challenging infections.

For PatientsFor ProvidersFor Health Systems
Collaborators & Affiliates

Trusted by leading institutions

FoundationThe Rockefeller Foundation
AcademicCornell Tech
Health SystemMayo Clinic Platform
AcademicWeill Cornell Medicine
AcademicSUNY Downstate
ResearchMetaSUB
ResearchFiocruz
StrategyMcKinsey InNYC
Featured Products

Our diagnostic and software products

From at-home diagnostic tests to pathogen genomics software and services used by health systems and global research consortia.

Diagnostic Test

BIOTIA‑ID Urine Test

Metagenomic detection of 44+ urogenital pathogens and a comprehensive AMR panel from a single urine sample. Accessible to patients via our telehealth partner.

Learn more
Diagnostic Test

BIOTIA‑ID Joint Fluid Test

Metagenomic detection of pathogens and resistance markers in synovial fluid for native and prosthetic joint infections.

Learn more
Genomics Software

BIOTIA-DX

Isolate identification and outbreak detection for hospitals and labs — turning routine sequencing into actionable infection control intelligence.

View case studies
Genomics Software

GeoSeeq

Cloud platform for genomic surveillance and microbiome research at scale, used by over 100 organizations across 100 countries.

Visit GeoSeeq
Featured technology

Powered by clinical metagenomics

Biotia is a leader in clinical metagenomic-based infectious disease diagnostics, a more advanced method of next-generation sequencing for comprehensive, pathogen-agnostic detection.

BIOTIA-ID
Clinical metagenomics
16s sequencing
Culture
Results turnaround
2–3 business days
2–5 business days
2–5 business days
Price
$249
$259
Varies
Resolution & detail
Detailed – Species or strain level resolution
Poor – Genus or species, with some groups unresolved
Detailed – Genus or species for species that grow
Kinds of microbes
Extensive – Bacteria, fungi, anaerobes, fastidious, and atypical pathogens
Limited – Bacteria only
Limited – Common bacteria and fungi only
Accuracy
High – limited contamination & false positives
Low – High potential for contamination & false positives
Low – High potential for contamination & false negatives
% of genome considered
Extensive – thousands of genes across the entire genome
Low – Looks at only one gene in a section of the genome
None, not applicable
Future biomarker and therapeutic insights
High
Low
None
Antimicrobial resistance prediction
High – Clinically-validated resistance reporting
None
Separate testing required
Clinical relevance
High – Healthy microbes filtered from report
Low – Reports non-pathogenic species
Low – Misses pathogenic species
Blog

Latest from Biotia

Read the blog, written by the Biotia team and our collaborators to help patients better understand UTI prevention, diagnostic, and treatment options.

Why Did My Urine Culture Come Back Negative?

Standard culture misses up to 1 in 3 UTIs. Here's why — and what you can do about it.

Diagnosing UTIs

What Is a UTI? Causes, Symptoms, and Diagnosis

A clinician-reviewed primer on urinary tract infections — what they are, who gets them, and how doctors confirm them.

UTI 101

UTI Symptoms: What to Look For and When to See a Doctor

The classic signs of cystitis, the warning signs of a kidney infection, and conditions that can mimic a UTI.

UTI 101
See all posts
About

Biotia

Biotia is a health tech company advancing infectious disease diagnostics for challenging infections. We pair clinical metagenomics and artificial intelligence to develop diagnostic and software solutions to help patients, providers, and health systems respond to infectious disease threats.

About Biotia
Biotia laboratory in Long Island City